Hardworker personal page - To The Moon

Hardworker

Hardworker

No personal profile

11Follow

6Followers

0Topic

0Badge

2022-11-17

‌[财迷] ‌

Sorry, the original content has been removed

2022-02-14

[Heartbreak]

Sorry, the original content has been removed

2022-02-12

[Miser]

China Approves Use of Pfizer's COVID Drug Paxlovid

2022-02-08

Sibeh sian

Pfizer Stock Dropped 5% after Posting Financial Results

2022-01-07

I totally agree

Sorry, the original content has been removed

2022-01-07

Must say the dividend for $The Kraft Heinz Company(KHC)$ is q stable and good all these years

2 Top Dividend Stocks That Are Yielding More Than 3%

2022-01-05

[Miser]

Sorry, the original content has been removed

2022-01-05

[Miser]

Pfizer doubles sales of COVID-19 pill to U.S. government to 20 million treatment courses

2022-01-04

$NVIDIA Corp(NVDA)$Hasn’t dropped below $290 for some time. A tad odd in light of the latest news today.

2021-12-30

$Pfizer(PFE)$ Sigh

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"4099037502678120","uuid":"4099037502678120","gmtCreate":1635934436123,"gmtModify":1706620742861,"name":"Hardworker","pinyin":"hardworker","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/88b11e17919cfda2568999348bed094b","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":6,"headSize":11,"tweetSize":16,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.07.31","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"44212b71d0be4ec88898348dbe882e03-3","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"President Tiger","description":"The transaction amount of the securities account reaches $1,000,000","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"93.45%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":"80.62%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":5,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":5,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":9963606660,"gmtCreate":1668653459551,"gmtModify":1676538091531,"author":{"id":"4099037502678120","authorId":"4099037502678120","name":"Hardworker","avatar":"https://static.tigerbbs.com/88b11e17919cfda2568999348bed094b","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099037502678120","authorIdStr":"4099037502678120"},"themes":[],"htmlText":"‌<a href=\"\">[财迷]&nbsp;</a>‌","listText":"‌<a href=\"\">[财迷]&nbsp;</a>‌","text":"‌[财迷] ‌","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9963606660","repostId":"2284350807","repostType":2,"isVote":1,"tweetType":1,"viewCount":254,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9095181966,"gmtCreate":1644851415157,"gmtModify":1676533967986,"author":{"id":"4099037502678120","authorId":"4099037502678120","name":"Hardworker","avatar":"https://static.tigerbbs.com/88b11e17919cfda2568999348bed094b","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099037502678120","authorIdStr":"4099037502678120"},"themes":[],"htmlText":"[Heartbreak]&nbsp;","listText":"[Heartbreak]&nbsp;","text":"[Heartbreak]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9095181966","repostId":"1156270518","repostType":2,"isVote":1,"tweetType":1,"viewCount":376,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9092241335,"gmtCreate":1644640922916,"gmtModify":1676533950178,"author":{"id":"4099037502678120","authorId":"4099037502678120","name":"Hardworker","avatar":"https://static.tigerbbs.com/88b11e17919cfda2568999348bed094b","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099037502678120","authorIdStr":"4099037502678120"},"themes":[],"htmlText":"[Miser]&nbsp;","listText":"[Miser]&nbsp;","text":"[Miser]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9092241335","repostId":"2210409526","repostType":2,"repost":{"id":"2210409526","pubTimestamp":1644633920,"share":"https://ttm.financial/m/news/2210409526?lang=&edition=fundamental","pubTime":"2022-02-12 10:45","market":"us","language":"en","title":"China Approves Use of Pfizer's COVID Drug Paxlovid","url":"https://stock-news.laohu8.com/highlight/detail?id=2210409526","media":"Reuters","summary":"BEIJING, Feb 12 (Reuters) - China's medical products regulator said on Saturday it has given conditi","content":"<html><head></head><body><p>BEIJING, Feb 12 (Reuters) - China&#39;s medical products regulator said on Saturday it has given conditional approval for Pfizer&#39;s COVID-19 treatment Paxlovid, making it the first oral anti-coronavirus pill approved in the country to treat the disease.</p><p>The National Medical Products Administration said Paxlovid has obtained conditional approval to treat adults who have mild to moderate COVID-19 and high risk of progressing to a severe condition. Further study on the drug needed to be conducted and submitted to the authority, it said.</p><p>It is not immediately clear if China is already in talks with Pfizer to procure the pill. Pfizer did not reply to a Reuters request for comment. </p></body></html>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China Approves Use of Pfizer's COVID Drug Paxlovid</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina Approves Use of Pfizer's COVID Drug Paxlovid\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-12 10:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/1-china-approves-pfizers-covid-024520927.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BEIJING, Feb 12 (Reuters) - China's medical products regulator said on Saturday it has given conditional approval for Pfizer's COVID-19 treatment Paxlovid, making it the first oral anti-coronavirus ...</p>\n\n<a href=\"https://finance.yahoo.com/news/1-china-approves-pfizers-covid-024520927.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4568":"美国抗疫概念","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4550":"红杉资本持仓","BK4007":"制药","PFE":"辉瑞","BK4124":"机动车零配件与设备","BK4534":"瑞士信贷持仓"},"source_url":"https://finance.yahoo.com/news/1-china-approves-pfizers-covid-024520927.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2210409526","content_text":"BEIJING, Feb 12 (Reuters) - China's medical products regulator said on Saturday it has given conditional approval for Pfizer's COVID-19 treatment Paxlovid, making it the first oral anti-coronavirus pill approved in the country to treat the disease.The National Medical Products Administration said Paxlovid has obtained conditional approval to treat adults who have mild to moderate COVID-19 and high risk of progressing to a severe condition. Further study on the drug needed to be conducted and submitted to the authority, it said.It is not immediately clear if China is already in talks with Pfizer to procure the pill. Pfizer did not reply to a Reuters request for comment.","news_type":1},"isVote":1,"tweetType":1,"viewCount":446,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9096120233,"gmtCreate":1644332843692,"gmtModify":1676533913725,"author":{"id":"4099037502678120","authorId":"4099037502678120","name":"Hardworker","avatar":"https://static.tigerbbs.com/88b11e17919cfda2568999348bed094b","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099037502678120","authorIdStr":"4099037502678120"},"themes":[],"htmlText":"Sibeh sian","listText":"Sibeh sian","text":"Sibeh sian","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9096120233","repostId":"1164228710","repostType":2,"repost":{"id":"1164228710","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1644321226,"share":"https://ttm.financial/m/news/1164228710?lang=&edition=fundamental","pubTime":"2022-02-08 19:53","market":"us","language":"en","title":"Pfizer Stock Dropped 5% after Posting Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1164228710","media":"Tiger Newspress","summary":"Pfizer stock dropped 5% after posting financial results.  Pfizer reported quarterly sales of $23.80 ","content":"<html><head></head><body><p>Pfizer stock dropped 5% after posting financial results.  Pfizer reported quarterly sales of $23.80 billion which missed the analyst consensus estimate of $24.20 billion by 1.65 percent.</p><p><img src=\"https://static.tigerbbs.com/4c3d1006e67e38521356972d425fdd53\" tg-width=\"1118\" tg-height=\"767\" referrerpolicy=\"no-referrer\"/></p><p>Pfizer (NYSE:PFE) reported quarterly earnings of $1.08 per share which beat the analyst consensus estimate of $0.87 by 24.14 percent.</p><p>This is a 157.14 percent increase over earnings of $0.42 per share from the same period last year.</p><p>The company reported quarterly sales of $23.80 billion which missed the analyst consensus estimate of $24.20 billion by 1.65 percent.</p><p>This is a 103.70 percent increase over sales of $11.68 billion the same period last year.</p><p></p><p></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Stock Dropped 5% after Posting Financial Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Stock Dropped 5% after Posting Financial Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-02-08 19:53</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Pfizer stock dropped 5% after posting financial results.  Pfizer reported quarterly sales of $23.80 billion which missed the analyst consensus estimate of $24.20 billion by 1.65 percent.</p><p><img src=\"https://static.tigerbbs.com/4c3d1006e67e38521356972d425fdd53\" tg-width=\"1118\" tg-height=\"767\" referrerpolicy=\"no-referrer\"/></p><p>Pfizer (NYSE:PFE) reported quarterly earnings of $1.08 per share which beat the analyst consensus estimate of $0.87 by 24.14 percent.</p><p>This is a 157.14 percent increase over earnings of $0.42 per share from the same period last year.</p><p>The company reported quarterly sales of $23.80 billion which missed the analyst consensus estimate of $24.20 billion by 1.65 percent.</p><p>This is a 103.70 percent increase over sales of $11.68 billion the same period last year.</p><p></p><p></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164228710","content_text":"Pfizer stock dropped 5% after posting financial results.  Pfizer reported quarterly sales of $23.80 billion which missed the analyst consensus estimate of $24.20 billion by 1.65 percent.Pfizer (NYSE:PFE) reported quarterly earnings of $1.08 per share which beat the analyst consensus estimate of $0.87 by 24.14 percent.This is a 157.14 percent increase over earnings of $0.42 per share from the same period last year.The company reported quarterly sales of $23.80 billion which missed the analyst consensus estimate of $24.20 billion by 1.65 percent.This is a 103.70 percent increase over sales of $11.68 billion the same period last year.","news_type":1},"isVote":1,"tweetType":1,"viewCount":354,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9006991314,"gmtCreate":1641569178109,"gmtModify":1676533630384,"author":{"id":"4099037502678120","authorId":"4099037502678120","name":"Hardworker","avatar":"https://static.tigerbbs.com/88b11e17919cfda2568999348bed094b","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099037502678120","authorIdStr":"4099037502678120"},"themes":[],"htmlText":"I totally agree","listText":"I totally agree","text":"I totally agree","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9006991314","repostId":"9006063711","repostType":1,"isVote":1,"tweetType":1,"viewCount":396,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9006905460,"gmtCreate":1641568416974,"gmtModify":1676533630178,"author":{"id":"4099037502678120","authorId":"4099037502678120","name":"Hardworker","avatar":"https://static.tigerbbs.com/88b11e17919cfda2568999348bed094b","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099037502678120","authorIdStr":"4099037502678120"},"themes":[],"htmlText":"Must say the dividend for <a href=\"https://ttm.financial/S/KHC\">$The Kraft Heinz Company(KHC)$</a> is q stable and good all these years","listText":"Must say the dividend for <a href=\"https://ttm.financial/S/KHC\">$The Kraft Heinz Company(KHC)$</a> is q stable and good all these years","text":"Must say the dividend for $The Kraft Heinz Company(KHC)$ is q stable and good all these years","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9006905460","repostId":"2201323382","repostType":2,"repost":{"id":"2201323382","pubTimestamp":1641451196,"share":"https://ttm.financial/m/news/2201323382?lang=&edition=fundamental","pubTime":"2022-01-06 14:39","market":"us","language":"en","title":"2 Top Dividend Stocks That Are Yielding More Than 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2201323382","media":"Motley Fool","summary":"They pay more than double the S&P 500 average.","content":"<html><head></head><body><p>Finding a good dividend stock isn&#39;t as simple as just looking for the highest yields. There are stocks that pay 10% or more, but those payouts may not necessarily be sustainable over a long period. A safer approach is to find a good balance of a high yield without too much risk. And with the stock market still scorching hot and at record levels, that has pushed yields down; the average <b>S&amp;P 500 </b>stock pays just 1.3%.</p><p><a href=\"https://laohu8.com/S/TWOA.U\">Two</a> investments that can generate more than double that recurring income are <b>Gilead Sciences </b>(NASDAQ:GILD) and <b>Kraft Heinz </b>(NASDAQ:KHC). Their payouts currently stand at more than 3% and offer investors a great mix of stability and recurring income.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/ca801f18b12adb3312a8502904386d79\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"/><span>Image source: Getty Images.</span></p><h2>1. Gilead Sciences</h2><p>Gilead Sciences currently pays investors a yield of 3.9%. If you were to invest $25,000 into the stock, that means you could be collecting nearly $1,000 over the next 12 months just in dividend income. That&#39;s nearly three times the $325 in dividends you could earn from the average S&amp;P 500 stock.</p><p>What&#39;s more, Gilead has also raised its payouts over the years, meaning you can earn more on your initial investment over time. Five years ago, the healthcare company was paying a quarterly dividend of $0.47 and today it is $0.71, a rise of more than 50%. Meanwhile, Gilead&#39;s current payout ratio is less than 50%, suggesting there is room for more rate hikes in the future.</p><p>Importantly, the business is doing well. For the period ended Sept. 30, 2021, sales grew 13% year over year to $7.4 billion, helped in part by the $1.9 billion it generated from Veklury, its COVID-19 treatment for hospitalized patients.</p><p>Gilead is also well-known for its HIV drug, Biktarvy, which continues to dominate its category with a 41% market share in the U.S. With new competition from generics, its sales fell by 8% during the latest period, which may concern some investors. However, the company notes that HIV-related revenue was up 4% year over year when excluding the impact of losses in exclusivity.</p><p>The company also has a promising treatment in lenacapavir, which if the U.S. Food and Drug Administration approves it this year, would be &#34;the first available six-month long-acting subcutaneous injection treatment for HIV.&#34;</p><p>What makes this a solid, income-generating investment is Gilead&#39;s impressive gross profit margin, which has stood no lower than 78% of revenue over the past five years. That, in turn, has helped the company consistently post a profit. And the company continues to work on keeping costs down. On its most recent earnings call, Gilead said it plans to open a facility in Maryland later this year which will automate many processes.</p><p>The present looks solid for Gilead Sciences, and the future is even more promising. For healthcare investors, this is a top dividend stock to buy today.</p><h2>2. Kraft Heinz</h2><p>Kraft Heinz pays an even higher dividend yield of 4.5%. A $25,000 investment here could generate more than $1,100 in annual dividend income for your portfolio. Kraft, however, hasn&#39;t been raising its payouts and actually slashed its dividend in 2019 -- from $0.625 to $0.40 per quarter. But by doing so, the dividend is much more sustainable. Over the past 12 months, Kraft&#39;s free cash of $3.2 billion has provided ample room for the $2 billion the company has distributed in dividends.</p><p>Although Kraft&#39;s 35% gross margin isn&#39;t as high as Gilead&#39;s, that hasn&#39;t stopped it from posting strong operating results. With just modest overhead (selling, general, and administrative costs, etc.) amounting to less than 15% of sales, the company is able to consistently bank about <a href=\"https://laohu8.com/S/AONE.U\">one</a>-fifth of sales as operating profit.</p><p>Sales growth has been a challenge of late. For the most recent quarter (ended Sept. 25, 2021), net sales totaled $6.3 billion, down a bit less than 2% from the prior-year period. And on a year-to-date basis, the company&#39;s top line has been flat from the previous year. There are also challenges ahead, especially with supply-chain issues and inflationary pressures chipping away at margins.</p><p>Yet, Kraft may be one of the safer stocks out there with respect to those challenges. Its popular food items are staples in restaurants and pantries across the country. And on the company&#39;s latest earnings call, Global Chief Financial Officer Paulo Luiz Araujo Basilio noted that Kraft has &#34;confidence in our ability to price the short-term inflation that we are seeing.&#34;</p><p>Whether you want a top dividend or just a stable stock to own in 2022, Kraft Heinz could be a great choice.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Top Dividend Stocks That Are Yielding More Than 3%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Top Dividend Stocks That Are Yielding More Than 3%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-06 14:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/05/2-top-dividend-stocks-that-are-yielding-more-than/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Finding a good dividend stock isn't as simple as just looking for the highest yields. There are stocks that pay 10% or more, but those payouts may not necessarily be sustainable over a long period. A ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/05/2-top-dividend-stocks-that-are-yielding-more-than/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4559":"巴菲特持仓","BK4139":"生物科技","GILD":"吉利德科学","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4504":"桥水持仓","BK4212":"包装食品与肉类","BK4532":"文艺复兴科技持仓","BK4558":"双十一","BK4566":"资本集团","KHC":"卡夫亨氏"},"source_url":"https://www.fool.com/investing/2022/01/05/2-top-dividend-stocks-that-are-yielding-more-than/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2201323382","content_text":"Finding a good dividend stock isn't as simple as just looking for the highest yields. There are stocks that pay 10% or more, but those payouts may not necessarily be sustainable over a long period. A safer approach is to find a good balance of a high yield without too much risk. And with the stock market still scorching hot and at record levels, that has pushed yields down; the average S&P 500 stock pays just 1.3%.Two investments that can generate more than double that recurring income are Gilead Sciences (NASDAQ:GILD) and Kraft Heinz (NASDAQ:KHC). Their payouts currently stand at more than 3% and offer investors a great mix of stability and recurring income.Image source: Getty Images.1. Gilead SciencesGilead Sciences currently pays investors a yield of 3.9%. If you were to invest $25,000 into the stock, that means you could be collecting nearly $1,000 over the next 12 months just in dividend income. That's nearly three times the $325 in dividends you could earn from the average S&P 500 stock.What's more, Gilead has also raised its payouts over the years, meaning you can earn more on your initial investment over time. Five years ago, the healthcare company was paying a quarterly dividend of $0.47 and today it is $0.71, a rise of more than 50%. Meanwhile, Gilead's current payout ratio is less than 50%, suggesting there is room for more rate hikes in the future.Importantly, the business is doing well. For the period ended Sept. 30, 2021, sales grew 13% year over year to $7.4 billion, helped in part by the $1.9 billion it generated from Veklury, its COVID-19 treatment for hospitalized patients.Gilead is also well-known for its HIV drug, Biktarvy, which continues to dominate its category with a 41% market share in the U.S. With new competition from generics, its sales fell by 8% during the latest period, which may concern some investors. However, the company notes that HIV-related revenue was up 4% year over year when excluding the impact of losses in exclusivity.The company also has a promising treatment in lenacapavir, which if the U.S. Food and Drug Administration approves it this year, would be \"the first available six-month long-acting subcutaneous injection treatment for HIV.\"What makes this a solid, income-generating investment is Gilead's impressive gross profit margin, which has stood no lower than 78% of revenue over the past five years. That, in turn, has helped the company consistently post a profit. And the company continues to work on keeping costs down. On its most recent earnings call, Gilead said it plans to open a facility in Maryland later this year which will automate many processes.The present looks solid for Gilead Sciences, and the future is even more promising. For healthcare investors, this is a top dividend stock to buy today.2. Kraft HeinzKraft Heinz pays an even higher dividend yield of 4.5%. A $25,000 investment here could generate more than $1,100 in annual dividend income for your portfolio. Kraft, however, hasn't been raising its payouts and actually slashed its dividend in 2019 -- from $0.625 to $0.40 per quarter. But by doing so, the dividend is much more sustainable. Over the past 12 months, Kraft's free cash of $3.2 billion has provided ample room for the $2 billion the company has distributed in dividends.Although Kraft's 35% gross margin isn't as high as Gilead's, that hasn't stopped it from posting strong operating results. With just modest overhead (selling, general, and administrative costs, etc.) amounting to less than 15% of sales, the company is able to consistently bank about one-fifth of sales as operating profit.Sales growth has been a challenge of late. For the most recent quarter (ended Sept. 25, 2021), net sales totaled $6.3 billion, down a bit less than 2% from the prior-year period. And on a year-to-date basis, the company's top line has been flat from the previous year. There are also challenges ahead, especially with supply-chain issues and inflationary pressures chipping away at margins.Yet, Kraft may be one of the safer stocks out there with respect to those challenges. Its popular food items are staples in restaurants and pantries across the country. And on the company's latest earnings call, Global Chief Financial Officer Paulo Luiz Araujo Basilio noted that Kraft has \"confidence in our ability to price the short-term inflation that we are seeing.\"Whether you want a top dividend or just a stable stock to own in 2022, Kraft Heinz could be a great choice.","news_type":1},"isVote":1,"tweetType":1,"viewCount":490,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9001711484,"gmtCreate":1641318436787,"gmtModify":1676533597317,"author":{"id":"4099037502678120","authorId":"4099037502678120","name":"Hardworker","avatar":"https://static.tigerbbs.com/88b11e17919cfda2568999348bed094b","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099037502678120","authorIdStr":"4099037502678120"},"themes":[],"htmlText":"[Miser]&nbsp;","listText":"[Miser]&nbsp;","text":"[Miser]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9001711484","repostId":"2201402076","repostType":2,"isVote":1,"tweetType":1,"viewCount":664,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9001711552,"gmtCreate":1641318407233,"gmtModify":1676533597317,"author":{"id":"4099037502678120","authorId":"4099037502678120","name":"Hardworker","avatar":"https://static.tigerbbs.com/88b11e17919cfda2568999348bed094b","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099037502678120","authorIdStr":"4099037502678120"},"themes":[],"htmlText":"[Miser]&nbsp;","listText":"[Miser]&nbsp;","text":"[Miser]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9001711552","repostId":"2201340732","repostType":2,"repost":{"id":"2201340732","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1641316260,"share":"https://ttm.financial/m/news/2201340732?lang=&edition=fundamental","pubTime":"2022-01-05 01:11","market":"us","language":"en","title":"Pfizer doubles sales of COVID-19 pill to U.S. government to 20 million treatment courses","url":"https://stock-news.laohu8.com/highlight/detail?id=2201340732","media":"Dow Jones","summary":"MW Pfizer doubles sales of COVID-19 pill to U.S. government to 20 million treatment courses\n\n\n  Pfiz","content":"<html><body><font class=\"NormalMinus1\" face=\"Arial\">\n<p>\nMW Pfizer doubles sales of COVID-19 pill to U.S. government to 20 million treatment courses\n</p>\n<p>\n  Pfizer Inc. <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> said it will sell an additional 10 million treatment courses of its oral therapy, Paxlovid, to treat COVID-19 to the U.S. government this year. That doubles the total amount of courses contracted by the U.S. government to 20 million, with 10 million courses to be delivered by the end of June and the rest to be delivered by the end of September. Meanwhile, Pfizer's stock sank 2.9% in afternoon trading. \"With the Omicron variant surging, the availability of and accessibility to treatment options is of utmost importance, as millions of people are being diagnosed with COVID-19 each and every day,\" said Pfizer Chief Executive Albert Bourla. \"With data showing significant reductions in hospitalizations and deaths, along with the potential for Paxlovid to maintain robust antiviral activity against Omicron, we believe this therapy will be an important tool in the fight against COVID-19.\" Pfizer's stock has still run up 29.7% over the past three months, while the S&amp;P 500  has gained 11.4%. \n</p>\n<p>\n  -Tomi Kilgore \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/END\">$(END)$</a> Dow Jones Newswires\n</p>\n<p>\n  January 04, 2022 12:11 ET (17:11 GMT)\n</p>\n<p>\n  Copyright (c) 2022 Dow Jones &amp; Company, Inc.\n</p>\n</font></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer doubles sales of COVID-19 pill to U.S. government to 20 million treatment courses</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer doubles sales of COVID-19 pill to U.S. government to 20 million treatment courses\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2022-01-05 01:11</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><font class=\"NormalMinus1\" face=\"Arial\">\n<p>\nMW Pfizer doubles sales of COVID-19 pill to U.S. government to 20 million treatment courses\n</p>\n<p>\n  Pfizer Inc. <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> said it will sell an additional 10 million treatment courses of its oral therapy, Paxlovid, to treat COVID-19 to the U.S. government this year. That doubles the total amount of courses contracted by the U.S. government to 20 million, with 10 million courses to be delivered by the end of June and the rest to be delivered by the end of September. Meanwhile, Pfizer's stock sank 2.9% in afternoon trading. \"With the Omicron variant surging, the availability of and accessibility to treatment options is of utmost importance, as millions of people are being diagnosed with COVID-19 each and every day,\" said Pfizer Chief Executive Albert Bourla. \"With data showing significant reductions in hospitalizations and deaths, along with the potential for Paxlovid to maintain robust antiviral activity against Omicron, we believe this therapy will be an important tool in the fight against COVID-19.\" Pfizer's stock has still run up 29.7% over the past three months, while the S&amp;P 500  has gained 11.4%. \n</p>\n<p>\n  -Tomi Kilgore \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/END\">$(END)$</a> Dow Jones Newswires\n</p>\n<p>\n  January 04, 2022 12:11 ET (17:11 GMT)\n</p>\n<p>\n  Copyright (c) 2022 Dow Jones &amp; Company, Inc.\n</p>\n</font></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"http://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2201340732","content_text":"MW Pfizer doubles sales of COVID-19 pill to U.S. government to 20 million treatment courses\n\n\n  Pfizer Inc. $(PFE)$ said it will sell an additional 10 million treatment courses of its oral therapy, Paxlovid, to treat COVID-19 to the U.S. government this year. That doubles the total amount of courses contracted by the U.S. government to 20 million, with 10 million courses to be delivered by the end of June and the rest to be delivered by the end of September. Meanwhile, Pfizer's stock sank 2.9% in afternoon trading. \"With the Omicron variant surging, the availability of and accessibility to treatment options is of utmost importance, as millions of people are being diagnosed with COVID-19 each and every day,\" said Pfizer Chief Executive Albert Bourla. \"With data showing significant reductions in hospitalizations and deaths, along with the potential for Paxlovid to maintain robust antiviral activity against Omicron, we believe this therapy will be an important tool in the fight against COVID-19.\" Pfizer's stock has still run up 29.7% over the past three months, while the S&P 500  has gained 11.4%. \n\n\n  -Tomi Kilgore \n\n\n \n\n\n$(END)$ Dow Jones Newswires\n\n\n  January 04, 2022 12:11 ET (17:11 GMT)\n\n\n  Copyright (c) 2022 Dow Jones & Company, Inc.","news_type":1},"isVote":1,"tweetType":1,"viewCount":445,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9001706538,"gmtCreate":1641310877708,"gmtModify":1676533596595,"author":{"id":"4099037502678120","authorId":"4099037502678120","name":"Hardworker","avatar":"https://static.tigerbbs.com/88b11e17919cfda2568999348bed094b","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099037502678120","authorIdStr":"4099037502678120"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/NVDA\">$NVIDIA Corp(NVDA)$</a>Hasn’t dropped below $290 for some time. A tad odd in light of the latest news today.","listText":"<a href=\"https://ttm.financial/S/NVDA\">$NVIDIA Corp(NVDA)$</a>Hasn’t dropped below $290 for some time. A tad odd in light of the latest news today.","text":"$NVIDIA Corp(NVDA)$Hasn’t dropped below $290 for some time. A tad odd in light of the latest news today.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9001706538","isVote":1,"tweetType":1,"viewCount":1897,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3573940971050145","authorId":"3573940971050145","name":"Michi","avatar":"https://static.tigerbbs.com/09c5b92ee759e13a58ffa83771d01f4f","crmLevel":2,"crmLevelSwitch":0,"idStr":"3573940971050145","authorIdStr":"3573940971050145"},"content":"What is the latest news?","text":"What is the latest news?","html":"What is the latest news?"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9009786495,"gmtCreate":1640794256109,"gmtModify":1676533542320,"author":{"id":"4099037502678120","authorId":"4099037502678120","name":"Hardworker","avatar":"https://static.tigerbbs.com/88b11e17919cfda2568999348bed094b","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099037502678120","authorIdStr":"4099037502678120"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/PFE\">$Pfizer(PFE)$</a> Sigh","listText":"<a href=\"https://ttm.financial/S/PFE\">$Pfizer(PFE)$</a> Sigh","text":"$Pfizer(PFE)$ Sigh","images":[{"img":"https://static.itradeup.com/news/d79bdf2c3a859005fa9c1428f0f5504a","width":"1125","height":"3342"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9009786495","isVote":1,"tweetType":1,"viewCount":551,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"hots":[{"id":9001706538,"gmtCreate":1641310877708,"gmtModify":1676533596595,"author":{"id":"4099037502678120","authorId":"4099037502678120","name":"Hardworker","avatar":"https://static.tigerbbs.com/88b11e17919cfda2568999348bed094b","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099037502678120","authorIdStr":"4099037502678120"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/NVDA\">$NVIDIA Corp(NVDA)$</a>Hasn’t dropped below $290 for some time. A tad odd in light of the latest news today.","listText":"<a href=\"https://ttm.financial/S/NVDA\">$NVIDIA Corp(NVDA)$</a>Hasn’t dropped below $290 for some time. A tad odd in light of the latest news today.","text":"$NVIDIA Corp(NVDA)$Hasn’t dropped below $290 for some time. A tad odd in light of the latest news today.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9001706538","isVote":1,"tweetType":1,"viewCount":1897,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3573940971050145","authorId":"3573940971050145","name":"Michi","avatar":"https://static.tigerbbs.com/09c5b92ee759e13a58ffa83771d01f4f","crmLevel":2,"crmLevelSwitch":0,"idStr":"3573940971050145","authorIdStr":"3573940971050145"},"content":"What is the latest news?","text":"What is the latest news?","html":"What is the latest news?"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9006905460,"gmtCreate":1641568416974,"gmtModify":1676533630178,"author":{"id":"4099037502678120","authorId":"4099037502678120","name":"Hardworker","avatar":"https://static.tigerbbs.com/88b11e17919cfda2568999348bed094b","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099037502678120","authorIdStr":"4099037502678120"},"themes":[],"htmlText":"Must say the dividend for <a href=\"https://ttm.financial/S/KHC\">$The Kraft Heinz Company(KHC)$</a> is q stable and good all these years","listText":"Must say the dividend for <a href=\"https://ttm.financial/S/KHC\">$The Kraft Heinz Company(KHC)$</a> is q stable and good all these years","text":"Must say the dividend for $The Kraft Heinz Company(KHC)$ is q stable and good all these years","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9006905460","repostId":"2201323382","repostType":2,"isVote":1,"tweetType":1,"viewCount":490,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9095181966,"gmtCreate":1644851415157,"gmtModify":1676533967986,"author":{"id":"4099037502678120","authorId":"4099037502678120","name":"Hardworker","avatar":"https://static.tigerbbs.com/88b11e17919cfda2568999348bed094b","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099037502678120","authorIdStr":"4099037502678120"},"themes":[],"htmlText":"[Heartbreak]&nbsp;","listText":"[Heartbreak]&nbsp;","text":"[Heartbreak]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9095181966","repostId":"1156270518","repostType":2,"repost":{"id":"1156270518","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1644829934,"share":"https://ttm.financial/m/news/1156270518?lang=&edition=fundamental","pubTime":"2022-02-14 17:12","market":"us","language":"en","title":"Vaccine Stocks Slipped in Premarket Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1156270518","media":"Tiger Newspress","summary":"Novavax, Moderna, BioNTech, and Pfizer fell between 1% and 5%.","content":"<html><head></head><body><p>Novavax, Moderna, BioNTech, and Pfizer fell between 1% and 5%.</p><p><img src=\"https://static.tigerbbs.com/fee74f1e9f7493e81a0a1c1d3630c332\" tg-width=\"701\" tg-height=\"612\" width=\"100%\" height=\"auto\"/></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaccine Stocks Slipped in Premarket Trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaccine Stocks Slipped in Premarket Trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-02-14 17:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Novavax, Moderna, BioNTech, and Pfizer fell between 1% and 5%.</p><p><img src=\"https://static.tigerbbs.com/fee74f1e9f7493e81a0a1c1d3630c332\" tg-width=\"701\" tg-height=\"612\" width=\"100%\" height=\"auto\"/></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","MRNA":"Moderna, Inc.","NVAX":"诺瓦瓦克斯医药","PFE":"辉瑞"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1156270518","content_text":"Novavax, Moderna, BioNTech, and Pfizer fell between 1% and 5%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":376,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9092241335,"gmtCreate":1644640922916,"gmtModify":1676533950178,"author":{"id":"4099037502678120","authorId":"4099037502678120","name":"Hardworker","avatar":"https://static.tigerbbs.com/88b11e17919cfda2568999348bed094b","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099037502678120","authorIdStr":"4099037502678120"},"themes":[],"htmlText":"[Miser]&nbsp;","listText":"[Miser]&nbsp;","text":"[Miser]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9092241335","repostId":"2210409526","repostType":2,"repost":{"id":"2210409526","pubTimestamp":1644633920,"share":"https://ttm.financial/m/news/2210409526?lang=&edition=fundamental","pubTime":"2022-02-12 10:45","market":"us","language":"en","title":"China Approves Use of Pfizer's COVID Drug Paxlovid","url":"https://stock-news.laohu8.com/highlight/detail?id=2210409526","media":"Reuters","summary":"BEIJING, Feb 12 (Reuters) - China's medical products regulator said on Saturday it has given conditi","content":"<html><head></head><body><p>BEIJING, Feb 12 (Reuters) - China&#39;s medical products regulator said on Saturday it has given conditional approval for Pfizer&#39;s COVID-19 treatment Paxlovid, making it the first oral anti-coronavirus pill approved in the country to treat the disease.</p><p>The National Medical Products Administration said Paxlovid has obtained conditional approval to treat adults who have mild to moderate COVID-19 and high risk of progressing to a severe condition. Further study on the drug needed to be conducted and submitted to the authority, it said.</p><p>It is not immediately clear if China is already in talks with Pfizer to procure the pill. Pfizer did not reply to a Reuters request for comment. </p></body></html>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China Approves Use of Pfizer's COVID Drug Paxlovid</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina Approves Use of Pfizer's COVID Drug Paxlovid\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-12 10:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/1-china-approves-pfizers-covid-024520927.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BEIJING, Feb 12 (Reuters) - China's medical products regulator said on Saturday it has given conditional approval for Pfizer's COVID-19 treatment Paxlovid, making it the first oral anti-coronavirus ...</p>\n\n<a href=\"https://finance.yahoo.com/news/1-china-approves-pfizers-covid-024520927.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4568":"美国抗疫概念","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4550":"红杉资本持仓","BK4007":"制药","PFE":"辉瑞","BK4124":"机动车零配件与设备","BK4534":"瑞士信贷持仓"},"source_url":"https://finance.yahoo.com/news/1-china-approves-pfizers-covid-024520927.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2210409526","content_text":"BEIJING, Feb 12 (Reuters) - China's medical products regulator said on Saturday it has given conditional approval for Pfizer's COVID-19 treatment Paxlovid, making it the first oral anti-coronavirus pill approved in the country to treat the disease.The National Medical Products Administration said Paxlovid has obtained conditional approval to treat adults who have mild to moderate COVID-19 and high risk of progressing to a severe condition. Further study on the drug needed to be conducted and submitted to the authority, it said.It is not immediately clear if China is already in talks with Pfizer to procure the pill. Pfizer did not reply to a Reuters request for comment.","news_type":1},"isVote":1,"tweetType":1,"viewCount":446,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9096120233,"gmtCreate":1644332843692,"gmtModify":1676533913725,"author":{"id":"4099037502678120","authorId":"4099037502678120","name":"Hardworker","avatar":"https://static.tigerbbs.com/88b11e17919cfda2568999348bed094b","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099037502678120","authorIdStr":"4099037502678120"},"themes":[],"htmlText":"Sibeh sian","listText":"Sibeh sian","text":"Sibeh sian","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9096120233","repostId":"1164228710","repostType":2,"isVote":1,"tweetType":1,"viewCount":354,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9009786495,"gmtCreate":1640794256109,"gmtModify":1676533542320,"author":{"id":"4099037502678120","authorId":"4099037502678120","name":"Hardworker","avatar":"https://static.tigerbbs.com/88b11e17919cfda2568999348bed094b","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099037502678120","authorIdStr":"4099037502678120"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/PFE\">$Pfizer(PFE)$</a> Sigh","listText":"<a href=\"https://ttm.financial/S/PFE\">$Pfizer(PFE)$</a> Sigh","text":"$Pfizer(PFE)$ Sigh","images":[{"img":"https://static.itradeup.com/news/d79bdf2c3a859005fa9c1428f0f5504a","width":"1125","height":"3342"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9009786495","isVote":1,"tweetType":1,"viewCount":551,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9963606660,"gmtCreate":1668653459551,"gmtModify":1676538091531,"author":{"id":"4099037502678120","authorId":"4099037502678120","name":"Hardworker","avatar":"https://static.tigerbbs.com/88b11e17919cfda2568999348bed094b","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099037502678120","authorIdStr":"4099037502678120"},"themes":[],"htmlText":"‌<a href=\"\">[财迷]&nbsp;</a>‌","listText":"‌<a href=\"\">[财迷]&nbsp;</a>‌","text":"‌[财迷] ‌","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9963606660","repostId":"2284350807","repostType":2,"repost":{"id":"2284350807","pubTimestamp":1668652092,"share":"https://ttm.financial/m/news/2284350807?lang=&edition=fundamental","pubTime":"2022-11-17 10:28","market":"us","language":"en","title":"Nvidia, Microsoft Partner to Build 'Massive' Cloud AI Supercomputer","url":"https://stock-news.laohu8.com/highlight/detail?id=2284350807","media":"Seeking Alpha","summary":"$Nvidia$ on Wednesday announced a multi-year collaboration with $Microsoft$ to build a \"massive\" cloud AI computer, which it said will be among the world's most powerful AI supercomputers.The supercomputer will be powered by Microsoft Azure's advanced supercomputing infrastructure combined with Nvidia's  GPUs, networking and full stack of AI software to help enterprises train, deploy and scale AI.Nvidia  will use Azure's scalable virtual machine instances to research and accelerate advances in g","content":"<html><head></head><body><p><a href=\"https://laohu8.com/S/NVDA\">Nvidia</a> on Wednesday announced a multi-year collaboration with <a href=\"https://laohu8.com/S/MSFT\">Microsoft</a> to build a &#34;massive&#34; cloud AI computer, which it said will be among the world&#39;s most powerful AI supercomputers.</p><p>The supercomputer will be powered by Microsoft Azure&#39;s advanced supercomputing infrastructure combined with Nvidia&#39;s (NVDA) GPUs, networking and full stack of AI software to help enterprises train, deploy and scale AI.</p><p>Nvidia (NVDA) will use Azure&#39;s scalable virtual machine instances to research and accelerate advances in generative AI.</p><p>The companies will also collaborate to optimize Microsoft&#39;s (MSFT) DeepSpeed deep learning optimization software.</p><p>Nvidia&#39;s (NVDA) full stack of AI workflows and software development kits will be made available to Azure enterprise customers.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nvidia, Microsoft Partner to Build 'Massive' Cloud AI Supercomputer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNvidia, Microsoft Partner to Build 'Massive' Cloud AI Supercomputer\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-11-17 10:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3908609-nvidia-microsoft-partner-to-build-massive-cloud-ai-supercomputer><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nvidia on Wednesday announced a multi-year collaboration with Microsoft to build a \"massive\" cloud AI computer, which it said will be among the world's most powerful AI supercomputers.The ...</p>\n\n<a href=\"https://seekingalpha.com/news/3908609-nvidia-microsoft-partner-to-build-massive-cloud-ai-supercomputer\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MSFT":"微软","ATVI":"动视暴雪"},"source_url":"https://seekingalpha.com/news/3908609-nvidia-microsoft-partner-to-build-massive-cloud-ai-supercomputer","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2284350807","content_text":"Nvidia on Wednesday announced a multi-year collaboration with Microsoft to build a \"massive\" cloud AI computer, which it said will be among the world's most powerful AI supercomputers.The supercomputer will be powered by Microsoft Azure's advanced supercomputing infrastructure combined with Nvidia's (NVDA) GPUs, networking and full stack of AI software to help enterprises train, deploy and scale AI.Nvidia (NVDA) will use Azure's scalable virtual machine instances to research and accelerate advances in generative AI.The companies will also collaborate to optimize Microsoft's (MSFT) DeepSpeed deep learning optimization software.Nvidia's (NVDA) full stack of AI workflows and software development kits will be made available to Azure enterprise customers.","news_type":1},"isVote":1,"tweetType":1,"viewCount":254,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9006991314,"gmtCreate":1641569178109,"gmtModify":1676533630384,"author":{"id":"4099037502678120","authorId":"4099037502678120","name":"Hardworker","avatar":"https://static.tigerbbs.com/88b11e17919cfda2568999348bed094b","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099037502678120","authorIdStr":"4099037502678120"},"themes":[],"htmlText":"I totally agree","listText":"I totally agree","text":"I totally agree","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9006991314","repostId":"9006063711","repostType":1,"isVote":1,"tweetType":1,"viewCount":396,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9001711484,"gmtCreate":1641318436787,"gmtModify":1676533597317,"author":{"id":"4099037502678120","authorId":"4099037502678120","name":"Hardworker","avatar":"https://static.tigerbbs.com/88b11e17919cfda2568999348bed094b","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099037502678120","authorIdStr":"4099037502678120"},"themes":[],"htmlText":"[Miser]&nbsp;","listText":"[Miser]&nbsp;","text":"[Miser]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9001711484","repostId":"2201402076","repostType":2,"repost":{"id":"2201402076","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1641315231,"share":"https://ttm.financial/m/news/2201402076?lang=&edition=fundamental","pubTime":"2022-01-05 00:53","market":"us","language":"en","title":"Pfizer to supply 10 mln additional courses of COVID-19 pill to U.S. govt","url":"https://stock-news.laohu8.com/highlight/detail?id=2201402076","media":"Reuters","summary":"Jan 4 (Reuters) - Pfizer Inc    said on Tuesday the U.S. government has agreed to buy additional 10 ","content":"<html><body><p>Jan 4 (Reuters) - Pfizer Inc    said on Tuesday the U.S. government has agreed to buy additional 10 million courses of its COVID-19 oral therapy, bringing the total amount of order by the government to 20 million courses. </p><p> (Reporting by Manojna Maddipatla in Bengaluru; Editing by Shinjini Ganguli)</p><p>((manojna.kalyani@thomsonreuters.com; +91  8061822700;))</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer to supply 10 mln additional courses of COVID-19 pill to U.S. govt</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer to supply 10 mln additional courses of COVID-19 pill to U.S. govt\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2022-01-05 00:53</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>Jan 4 (Reuters) - Pfizer Inc    said on Tuesday the U.S. government has agreed to buy additional 10 million courses of its COVID-19 oral therapy, bringing the total amount of order by the government to 20 million courses. </p><p> (Reporting by Manojna Maddipatla in Bengaluru; Editing by Shinjini Ganguli)</p><p>((manojna.kalyani@thomsonreuters.com; +91  8061822700;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4534":"瑞士信贷持仓","BK4568":"美国抗疫概念","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4550":"红杉资本持仓","BK4007":"制药"},"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2201402076","content_text":"Jan 4 (Reuters) - Pfizer Inc    said on Tuesday the U.S. government has agreed to buy additional 10 million courses of its COVID-19 oral therapy, bringing the total amount of order by the government to 20 million courses.  (Reporting by Manojna Maddipatla in Bengaluru; Editing by Shinjini Ganguli)((manojna.kalyani@thomsonreuters.com; +91  8061822700;))","news_type":1},"isVote":1,"tweetType":1,"viewCount":664,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9001711552,"gmtCreate":1641318407233,"gmtModify":1676533597317,"author":{"id":"4099037502678120","authorId":"4099037502678120","name":"Hardworker","avatar":"https://static.tigerbbs.com/88b11e17919cfda2568999348bed094b","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099037502678120","authorIdStr":"4099037502678120"},"themes":[],"htmlText":"[Miser]&nbsp;","listText":"[Miser]&nbsp;","text":"[Miser]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9001711552","repostId":"2201340732","repostType":2,"isVote":1,"tweetType":1,"viewCount":445,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}